

R2581

Abstract (publication only)

Activity of tigecycline and comparator agents among Gram-positive and Gram-negative pathogens in France; the TEST Program 2006-2012

M. Hackel*, S. Hawser, D. Hoban, D. Biedenbach, R. Badal, S. Bouchillon, J. Johnson, H. Leister-Tebbe (Schaumburg, US; Epalinges, CH; Collegenille, US)

Objectives: The Tigecycline European Surveillance Trial (TEST), a comprehensive surveillance study, allows assessment of trends in antimicrobial activity over time. Such monitoring assists in investigating resistance rates globally, regionally or by country. The current report describes susceptibility of 7,713 gram-negative and 3,748 gram-positive isolates, including resistant phenotypes, from France to tigecycline and comparators. **Methods:** A total of 11,461 clinical isolates were collected from multiple infection sources in France during 2006 – October 2012. Susceptibility testing was performed following CLSI guidelines and interpreted using EUCAST clinical breakpoints. **Results:** Susceptibility of the 11,461 isolates to tigecycline is shown below: %S, percent susceptible; * %S based on FDA breakpoint; VRE, vancomycin-resistant enterococci; ESBL, extended spectrum beta-lactamase; MRSA, methicillin-resistant *S. aureus*; na, not determined, no clinical breakpoints exist for this drug / organism combination **Conclusions:** Since the introduction of tigecycline in France in 2006, the agent has maintained excellent activity against gram-positive and -negative pathogens. Susceptibility of 7,713 gram-negative isolates ranged from 79.4% to 99.2%, with MIC₉₀s of ≤2 mg/L. Greater than 90% of ESBL+ *E. coli* and *K. oxytoca* showed susceptibility to tigecycline, while in vitro activity was slightly lower for ESBL+ *K. pneumoniae* with 78.6% susceptible. Susceptibility of the 3,748 gram-positive isolates, ranged from 99% to 100%, including VRE and MRSA. Continued monitoring of isolates from France through the TEST program is warranted.

Organism	N	MIC₉₀ (mg/L)	% S
<i>Acinetobacter</i> spp.	1118	1	na
<i>Enterobacter</i> spp.	1928	2	85.1
<i>Enterococcus</i> spp.	1142	0.25	99.8
VRE	24	0.25	100
<i>Escherichia coli</i>	1979	0.5	99.2
<i>E. coli</i> , ESBL+	246	0.5	98.8
<i>Klebsiella</i> spp.	1898	1	90.2
<i>K. oxytoca</i> , ESBL+	14	1	92.9
<i>K. pneumoniae</i> , ESBL+	243	2	78.6
<i>Serratia</i> spp.	790	2	79.4
<i>Staphylococcus aureus</i>	1831	0.25	100
<i>S. aureus</i> , MRSA	441	0.25	100
<i>Streptococcus pneumoniae</i>	775	0.06	98.7*